Last week, The Wellcome Trust released a report on the future relationship for scientific research between the UK and the European Union (EU) following Brexit. Drawing on the views of 200 organisations and individuals, the report recommends maintaining a close partnership through the establishment of an EU-UK research and innovation agreement that covers funding, regulation and research policy, and the movement of researchers.
On funding, the report finds that the EU's Framework Programmes are the most efficient and practical way to support collaboration, and recommends that the UK seek to maintain involvement in this funding system through securing Associated Country status. Similarly, the report outlines several areas where the EU and the UK should continue to cooperate on the regulation of basic and clinical research, and argues that the current UK immigration system for non-European Economic Area (EEA) nationals is poorly suited to supporting the needs of the research community, recommending instead full researcher mobility between the EEA and the UK post Brexit.
Overall, the report makes a compelling health, economic, and social case for maintaining a close relationship with the EU after Brexit but fails to articulate the clear conclusion of its analysis: that the most effective way to support UK and European scientific research is for the UK to remain in the EU. In this regard, the report mirrors the approach of other leading civil society institutions in assuming that the decision about whether to leave the EU is set in stone. The result is that the trust has limited its ability to advocate maximally in the public interest.
It is important to recognise that it is near unprecedented for a scientific funding agency to wade into such a controversial debate. In the context of a public discourse that is yet to settle on a conception of what Brexit really means beyond debates over notions of "sovereignty" and "control", an evidence-informed focus on concrete actions needed to minimise the impact of Brexit on research is welcome. Over 18 months after the referendum result, it is time for practical considerations to start taking precedence over ideological posturing-the health and prosperity of the UK depend on it. n The Lancet Wellcome seeks Brexit carve-out for UK research The possibility of regeneration fascinates us as much today as it did the ancient Greeks. In the story of Prometheus, an eagle was sent to peck his liver each day as punishment, while at night it regrew. Stem cells have a similar mythical character-part fact, part fantasy-that captures the imagination but also blurs reality. In today's issue, we publish the Lancet Commission: Stem Cells and Regenerative Medicine (published online Oct 4, 2017) to assess advances in the field, including gene therapy, since our last Series on the topic in 2013, and how to plan future developments in a way that both promotes science and protects the public. The commissioners emphasise the importance of well funded basic science that led to the insights and techniques that have made stem cell therapies possible. However, in-vitro findings have not always been replicated in humans. To improve translation, they suggest wider collaboration with clinician-scientists. The report notes that many regenerative therapies appeal to potentially vulnerable people, which raises concerns about ethics, safety (particularly for unregulated autologous cell use), and financial structures for development and marketing. At the same time, the enormous advantage of curative gene therapy for a disease like Duchenne muscular dystrophy, which can restore independence and reduce health-care costs, is clear. To guide practice, the Commissioners propose a social contract that emphasises best science, equitable funding, strong governance, and transparent engagement with patients and the public.
Prometheus was punished by Zeus for stealing fire and giving it to humans, which enabled civilisation. In other interpretations, Prometheus is associated with scientific enquiry. Since our previous Series, the spark of regenerative medicine has become a flame that offers vast potential benefits, such as limbal stem cells licensed for corneal re pair. But dangers persist that are incompletely understood, and the best way to harness stem cells and genes to alle viate true clinical need is unclear. The Commission provides a welcome mechanism to move past the smoke of hype and cultivate the flame of hope. n The Lancet 
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